Macleods Pharma recalls 10,000 bottles of anti-bacterial medication in US

Macleods Pharmaceuticals is recalling around 10,000 bottles of generic antibiotic medication in the US market due to a labelling error, according to the US health regulator

Macleods Pharma recalls 10,000 bottles of anti-bacterial medication in US
Macleods Pharma recalls 10,000 bottles of anti-bacterial medication in US
Press Trust of India New Delhi
2 min read Last Updated : Jan 26 2023 | 4:31 PM IST

Macleods Pharmaceuticals is recalling around 10,000 bottles of generic antibiotic medication in the US market due to a labelling error, according to the US health regulator.

As per the latest enforcement report by the US Food and Drug Administration (USFDA), Macleods Pharma Inc, a US-based unit of the company, is recalling 10,052 bottles of Levofloxacin tablets, which are used to treat different types of bacterial infections.

The company is recalling the affected lot due to"mismatching of the embossing on the tablets with the embossing mentioned in the package insert in the distributed bottles."

Macleods manufactured the affected lot in its Baddi-based manufacturing plant in Himachal Pradesh.

The company initiated the Class III recall in the US and Puerto Rico on January 5.

As per the USFDA, a Class III recall is initiated in a situation in which use of, or exposure to, a violative product is not likely to cause adverse health consequences.

The US generic drug market was estimated to be around USD 115.2 billion in 2019. It is by far the largest market for pharmaceutical products in the world.

In the last financial year, India's pharma exports stood at around USD 24.62 billion with the US, the UK, South Africa, Russia, and Nigeria emerging as the top five destinations.

The Mumbai-based company has presence across various therapeutic segments including anti-infectives, cardiovascular, anti-diabetic, dermatology, and hormone treatment.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

Subscribe to Business Standard digital and get complimentary access to The New York Times

Quarterly Starter

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

Save 46%

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Access to Exclusive Premium Stories Online

  • Over 30 behind the paywall stories daily, handpicked by our editors for subscribers

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :pharmaceutical firmsHealthcare sectorUSA

First Published: Jan 26 2023 | 4:31 PM IST

Next Story